Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirna-tgf-b1 + sirna-cox-2
- Development stage
- Phase 2
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intratumoral
01
Overview
A combination therapy consisting of two small interfering RNAs (siRNAs): one targeting **TGF-beta 1 (TGF-β1)** mRNA and the other targeting **COX-2 (Cyclooxygenase-2)** mRNA. The dual siRNA approach **simultaneously silences both genes**, leading to the downregulation of profibrotic and proinflammatory factors, induction of apoptosis in target cells (e.g., fibroblasts or tumor cells), reduced proliferation, migration, and invasion in preclinical models of hypertrophic scarring and cancer. This combination is often delivered using a nanoparticle carrier such as branched histidine-lysine polymers to enhance cellular uptake. In oncology, co-delivery can increase tumor T cell infiltration and augment the activity of immune checkpoint inhibitors, especially in hepatocellular carcinoma and other tumors characterized by TGF-β1/COX-2-mediated immune exclusion[1][2][3][4].
- Brand names
- Cotsiranib
- Other names
- combination siRNA targeting TGF-beta 1 and COX-2COX-2/TGF-β1 siRNA cocktail
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on sirna-tgf-b1 + sirna-cox-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirna-tgf-b1 + sirna-cox-2.